Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Rapid Response Innovation Awards, 2010
    MicroRNAs as Biomarkers for Parkinson's Disease; A Comparison of CSF and Blood

    Objective/Rationale:
    We, and many other groups, hypothesize that miRNAs have the potential to be selective and sensitive diagnostic indicators for Parkinson’s disease. The focus of this project is to...

  • Rapid Response Innovation Awards, 2010
    The Role of Alpha-synuclein in the Pathogenesis of Parkinson's Disease in a Pre-clinical Model

    Objective/Rationale: 
    We hypothesized that alpha-synuclein increased level and accumulation within the target neurons in the affected model acts as a trigger mechanism for activation of additional...

  • Target Validation, 2010
    Validation of FKBP Inhibitors to Target Alpha-synuclein Pathology in Pre-clinical Model Brain

    Objective/Rationale: 
    FK506 Binding Proteins (FKBPs) are enzymes that play a role in protein folding. FKBPs are highly expressed in human brain and are thought to be involved in neurodegenerative...

  • Therapeutics Development Initiative, 2010
    Evaluation of the Neuroprotectivity Ability of Zymes' Water-soluble CoQ10 (WS-CoQ10) in Pre-clinical Models of PD; Preclinical Validation and Dose Optimization for Clinical Study

    Objective/Rationale:
    Coenzyme Q10 is a lipid soluble naturally occurring compound essential for energy production and defence against oxidative stress.  Recent clinical studies indicate that it may...

  • Alpha-Synuclein Therapeutics, 2010
    Use of the Orally Administered Pharmacological Chaperone AT3375 to Reduce Alpha-synuclein Levels in the Brain of Thy-1 Alpha-synuclein Small Models

    Objective/Rationale: 
    Mutations in the GBA1 gene increase the risk of Parkinson’s. These mutations reduce the activity of the enzyme glucocerebrosidase (GCase), which is deficient in the lysosomal...

  • Target Validation, 2010
    Kynurenine 3-monooxygenase (KMO) as a Target to Develop Drugs to Block Progression of Parkinson's Disease

    Objective/Rationale:
    These studies will validate the enzyme kynurenine 3-monooxygenase (KMO) as a target to develop drugs to treat PD (PD). KMO is expressed in cells involved in inflammation, which is...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.